de Bruin P C, Beljaards R C, van Heerde P, Van Der Valk P, Noorduyn L A, Van Krieken J H, Kluin-Nelemans J C, Willemze R, Meijer C J
Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Histopathology. 1993 Aug;23(2):127-35. doi: 10.1111/j.1365-2559.1993.tb00470.x.
The histological, immunophenotypic and clinical features of 19 primary cutaneous anaplastic large cell lymphomas (cutaneous ALCL) were compared with those of 18 primary nodal anaplastic large cell lymphomas (nodal ALCL) of T-cell or null cell type. Although cutaneous ALCL and nodal ALCL had identical morphological features, differences in surface marker expression and clinical behaviour were found. Immunophenotypical differences concerned the expression of epithelial membrane antigen (82% of the nodal ALCL were positive v. none of the cutaneous ALCL) and the cutaneous lymphocyte antigen (HECA-452), a possible skin-homing receptor on cutaneous T-lymphocytes (most tumour cells in 44% of cutaneous ALCL cases were positive, whereas nodal ALCL showed expression of HECA-452 on only few tumour cells (< 25%) in 18% of cases tested). Loss of T-cell markers was more pronounced for nodal ALCL. Patients with cutaneous ALCL were generally older (median 61 years) than patients with nodal ALCL (median 24 years) and, in contrast to the latter group, did not show bimodal age distribution. Survival after 4 years, using lymphoma-related death as an end-point, differed significantly between cutaneous ALCL and nodal ALCL; 92% for cutaneous ALCL and 65% for nodal ALCL (P = 0.04). The better survival of cutaneous ALCL patients could not be ascribed to differences in age, stage or initial mode of treatment. These data indicate that differences in immunophenotype and clinical behaviour exist between morphologically identical primary cutaneous and primary node-based ALCL. They indicate that the primary site is an important prognostic factor in predicting the clinical outcome of ALCL.
对19例原发性皮肤间变性大细胞淋巴瘤(皮肤ALCL)与18例T细胞或无细胞型原发性淋巴结间变性大细胞淋巴瘤(淋巴结ALCL)的组织学、免疫表型及临床特征进行了比较。虽然皮肤ALCL和淋巴结ALCL具有相同的形态学特征,但在表面标志物表达和临床行为方面存在差异。免疫表型差异涉及上皮膜抗原的表达(82%的淋巴结ALCL呈阳性,而皮肤ALCL均为阴性)以及皮肤淋巴细胞抗原(HECA-452),它可能是皮肤T淋巴细胞上的一种皮肤归巢受体(44%的皮肤ALCL病例中大多数肿瘤细胞呈阳性,而在18%检测的病例中,淋巴结ALCL仅少数肿瘤细胞(<25%)表达HECA-452)。淋巴结ALCL中T细胞标志物的丢失更为明显。皮肤ALCL患者通常比淋巴结ALCL患者年龄大(中位年龄61岁对24岁),且与后一组不同,未表现出双峰年龄分布。以淋巴瘤相关死亡为终点,4年后皮肤ALCL和淋巴结ALCL的生存率有显著差异;皮肤ALCL为92%,淋巴结ALCL为65%(P=0.04)。皮肤ALCL患者较好的生存率不能归因于年龄、分期或初始治疗方式的差异。这些数据表明,形态学相同的原发性皮肤和原发性淋巴结型ALCL在免疫表型和临床行为上存在差异。它们表明原发部位是预测ALCL临床结局的一个重要预后因素。